Alfasigma Gets Green Light for Commercialization of Jyseleca in Europe

Alfasigma will soon start to market Jyseleca in Europe. The Italian pharmaceutical company has announced that the transfer of marketing authorization for this medicine in the European Union (EU) has been completed, after the Italian group purchased the drug from Galapagos for 170 million euros.

Following confirmation from the European Commission (EC) for the transfer of marketing of the drug, after receiving the approval of the European Medicines Agency (EMA) on August 2nd, the marketing of Jyseleca is, from now on, the responsibility of Alfasigma.

With this acquisition, Alfasigma consolidates its commitment to specialty pharmaceutical products and adds a drug to its portfolio in the therapeutic areas of gastroenterology and rheumatology.

Alfasigma will take over the marketing of the drug Jyseleca after acquiring it from Galápagos NV

Jyseleca is a once-daily, oral, Janus kinase (JAK1)-preferred inhibitor drug approved for two markers, rheumatoid arthritis, approved in 2020, and ulcerative colitis, approved in 2021.

Alfasigma’s Spanish subsidiary is located in Tortosa, Barcelona, ​​and occupies an area of ​​1,600 square metres. It employs 1,475 people and has a portfolio of fifty references. The company’s Spanish branch is the result of the merger of Sigma-Tau and Alfa Wasserman in 2015 and, previously, of the merger of Geve Laboratories, in Tortosa, with Bama Laboratories, in 2003.

For its part, Galapagos is a global biotechnology company with operations in Europe and the United States dedicated to the development of transformative medicines to achieve more years and a better quality of life. The company combines science, technology and collaborative approaches to create a portfolio of therapies and biological products in oncology and immunology.

Filgotinib is marketed as Jyseleca in Europe and Japan for the treatment of adults with moderately to severely active RA who have responded inadequately or are intolerant to one or more disease-modifying antirheumatic drugs. Filgotinib is also used for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us